Monika Fischer, MD
Gastroenterology · Indianapolis, INNPI 1023264900
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 33.2% of the total. 2025 is the largest year on record at $74,015, 2.8 times the $25,999 reported in 2019. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $651.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$86K
- E.r. Squibb & Sons, L.L.C.$31K
- Ferring Pharmaceuticals Inc.$30K
- Takeda Pharmaceuticals U.S.A., Inc.$24K
- Lilly USA, LLC$19K
- Pfizer$18K
- plus $49K from 12 others
Across 216 payments — averaging $11,831 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$903K
- E.r. Squibb & Sons, L.L.C.$494K
- AbbVie$438K
- Takeda Pharmaceuticals U.S.A., Inc.$216K
- Covidien LP$181K
- Bristol Myers Squibb$116K
- plus $206K from 5 others
What the payments were for
- Consulting fees$120,66747%
- Speaking & faculty fees$103,38740%
- Travel & lodging$22,9879%
- Food & beverage$10,9024%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 90 | $85,670 |
| E.r. Squibb & Sons, L.L.C. | 27 | $31,022 |
| Ferring Pharmaceuticals Inc. | 19 | $30,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 59 | $24,277 |
| Lilly USA, LLC | 30 | $19,216 |
| Pfizer | 24 | $18,475 |
| Janssen Scientific Affairs, LLC | 19 | $15,763 |
| AbbVie | 96 | $13,191 |
| Eli Lilly | 9 | $10,941 |
| Bristol Myers Squibb | 9 | $3,926 |
| Aimmune Therapeutics, Inc. | 6 | $3,394 |
| Rebiotix Inc. | 1 | $800 |
| GI Supply, Inc. | 1 | $600 |
| Biogen | 2 | $300 |
| Medtronic | 1 | $129 |
| Celltrion USA Inc. | 1 | $32 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Genentech, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$258,031 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 87 | $2,258,009 |
| Skyrizi On-BodyRisankizumab-Rzaa | 87 | $1,764,747 |
| Humira(Cf) PenAdalimumab | 31 | $496,762 |
| RinvoqUpadacitinib | 28 | $224,967 |
| EntyvioVedolizumab | 17 | $147,518 |
| Humira(Cf)Adalimumab | 12 | $76,126 |
| CreonLipase/Protease/Amylase | 11 | $52,128 |
| Mesalamine | 44 | $21,577 |
| MotegrityPrucalopride Succinate | 12 | $6,776 |
| Colestipol Hcl | 35 | $3,840 |
| Balsalazide Disodium | 18 | $3,717 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 23 | $2,956 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $2,104 |
| LoperamideLoperamide Hcl | 26 | $1,822 |
| Azathioprine | 32 | $1,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $85,670 | $2,258,00987 claims |
| AbbVieRinvoq, Humira(Cf), Creon | $13,191 | $353,22151 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity | $24,277 | $154,29329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Indianapolis
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Naga ChalasaniIndianapolis$255K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Glen LehmanIndianapolis$87K
- Samer GawriehIndianapolis$78K
- Stuart ShermanIndianapolis$52K
- Mohammad Al HaddadIndianapolis$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.